Efficient Data. Effective Medicine
OWKIN uses AI and machine learning to augment medical and biology research. Its proprietary platform, Owkin Socrates, uses machine learning technology to integrate biomedical images, genomics and clinical data to discover biomarkers and mechanisms associated with diseases and treatment outcomes. The company develops scientific collaborations with top-tier medical institutions and partners with leading pharmaceutical companies. Owkin has developed a state-of-the-art federated learning technology in healthcare to overcome the sharing problems associated with medical data, building collective intelligence from distributed data at scale while preserving privacy and security.
Our data scientists are among the best in the world, with several Kaggle Masters, DREAM Challenge top performers, and publications in ICML, NIPS and other top scientific journals. OWKIN is proud of its unique physician-scientist team trained in Weill Cornell and Paris University as well as pharma and CRO senior directors from Novartis, Roche, and Parexel.. Owkin is backed by renowned investors — such as Google Ventures and F-Prime — as well as a distinguished scientific board chaired by Bruno Strigini, former CEO of Novartis Oncology. To build this vision, Owkin is growing rapidly, with offices located in the USA, France, and UK.